HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
GLS
glutaminase
Chromosome 2 Β· 2q32.2
NCBI Gene: 2744Ensembl: ENSG00000115419.14HGNC: HGNC:4331UniProt: H7C201
206PubMed Papers
23Diseases
1Drugs
18Pathogenic Variants
RESEARCH IMPACT
Trending
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
glutaminase activityprotein bindingprotein homotetramerizationnegative regulation of L-glutamine biosynthetic processglobal developmental delay, progressive ataxia, and elevated glutaminegenetic developmental and epileptic encephalopathyinfantile cataract, skin abnormalities, glutamate excess, and impaired intellectual developmentneurodegenerative disease
✦AI Summary

GLS encodes glutaminase, a mitochondrial enzyme that catalyzes the hydrolysis of glutamine to glutamate, playing a central role in cellular glutamine metabolism and energy production 1. The enzyme exhibits high expression in various cancer types, including pancreatic ductal adenocarcinoma and colorectal cancer, where it promotes tumor cell proliferation through glutaminolysis 12. GLS activity is regulated by post-translational modifications, particularly succinylation at K311, which enhances oligomerization and enzymatic activity during oxidative stress 1. The enzyme functions in cellular osmoregulation, as demonstrated in corneal epithelial cells under hyperosmotic stress, where GLS-1 upregulation helps maintain ATP production through glutamate conversion for the tricarboxylic acid cycle 3. Cancer cells can adapt to glutamine deprivation or GLS inhibition through compensatory metabolic pathways, such as the serine synthesis pathway, which can produce Ξ±-ketoglutarate when glutamate is depleted 4. RNA-binding protein HuR regulates GLS mRNA alternative splicing and stability, controlling the expression of different glutaminase isoforms (GAC and KGA) associated with cancer progression 5. Genetic variations in GLS, including GCA repeat polymorphisms, may influence disease susceptibility and clinical outcomes 67.

Sources cited
1
GLS catalyzes glutamine hydrolysis, is highly expressed in pancreatic cancer, and is regulated by succinylation
PMID: 33991485
2
GLS promotes colorectal cancer progression through glutamine metabolism
PMID: 39151722
3
Cancer cells can adapt to GLS inhibition through alternative metabolic pathways
PMID: 39192144
4
GLS-1 upregulation is an osmoregulatory response in corneal epithelial cells
PMID: 40360154
5
HuR regulates GLS mRNA alternative splicing and isoform expression in breast cancer
PMID: 38965208
6
GLS genetic polymorphisms are associated with lung cancer susceptibility
PMID: 37258469
7
GLS GCA repeat variations may influence spinocerebellar ataxia disease onset
PMID: 39699045
Disease Associationsβ“˜23
global developmental delay, progressive ataxia, and elevated glutamineOpen Targets
0.64Moderate
genetic developmental and epileptic encephalopathyOpen Targets
0.61Moderate
infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual developmentOpen Targets
0.50Moderate
neurodegenerative diseaseOpen Targets
0.37Weak
glutaminase deficiencyOpen Targets
0.37Weak
genetic disorderOpen Targets
0.34Weak
multinodular goiterOpen Targets
0.30Weak
response to antihypertensive drugOpen Targets
0.30Weak
poisoningOpen Targets
0.29Weak
systemic lupus erythematosusOpen Targets
0.28Weak
esophageal atresia/tracheoesophageal fistulaOpen Targets
0.26Weak
Tracheoesophageal fistulaOpen Targets
0.26Weak
hemorrhagic diseaseOpen Targets
0.21Weak
primary biliary cirrhosisOpen Targets
0.20Weak
B-cell acute lymphoblastic leukemiaOpen Targets
0.16Weak
hypertensionOpen Targets
0.15Weak
essential hypertensionOpen Targets
0.15Weak
HepatomegalyOpen Targets
0.15Weak
neoplasmOpen Targets
0.13Weak
cancerOpen Targets
0.11Weak
CASGID syndromeUniProt
Developmental and epileptic encephalopathy 71UniProt
Global developmental delay, progressive ataxia, and elevated glutamineUniProt
Pathogenic Variants18
NM_014905.5(GLS):c.671_681del (p.Phe224fs)Pathogenic
not provided|Global developmental delay, progressive ataxia, and elevated glutamine
β˜…β˜…β˜†β˜†2026β†’ Residue 224
NM_014905.5(GLS):c.386+2T>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_014905.5(GLS):c.637C>T (p.Gln213Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 213
NM_014905.5(GLS):c.923dup (p.Tyr308Ter)Pathogenic
Global developmental delay, progressive ataxia, and elevated glutamine|not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 308
NM_014905.5(GLS):c.338_339dup (p.Ala114fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 114
NM_014905.5(GLS):c.1709G>A (p.Arg570Gln)Likely pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 570
NM_014905.5(GLS):c.1270T>C (p.Cys424Arg)Likely pathogenic
Developmental and epileptic encephalopathy, 71
β˜…β˜†β˜†β˜†2023β†’ Residue 424
NM_014905.5(GLS):c.1072-2A>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2022
NM_014905.5(GLS):c.1460dup (p.Ile488fs)Pathogenic
Developmental and epileptic encephalopathy, 71
β˜…β˜†β˜†β˜†2022β†’ Residue 488
NM_014905.5(GLS):c.241C>T (p.Gln81Ter)Pathogenic
Developmental and epileptic encephalopathy, 71
β˜…β˜†β˜†β˜†2019β†’ Residue 81
NM_014905.5(GLS):c.695dup (p.Asp232fs)Pathogenic
Developmental and epileptic encephalopathy, 71
β˜…β˜†β˜†β˜†2019β†’ Residue 232
NM_014905.5(GLS):c.815G>A (p.Arg272Lys)Pathogenic
Developmental and epileptic encephalopathy, 71
β˜…β˜†β˜†β˜†2019β†’ Residue 272
NM_014905.5(GLS):c.866A>T (p.Lys289Ile)Likely pathogenic
Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development
β˜…β˜†β˜†β˜†β†’ Residue 289
NM_014905.5(GLS):c.1382A>T (p.His461Leu)Pathogenic
Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development
β˜†β˜†β˜†β˜†2025β†’ Residue 461
NM_014905.5(GLS):c.1445C>G (p.Ser482Cys)Pathogenic
Infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development
β˜†β˜†β˜†β˜†2025β†’ Residue 482
NM_014905.5(GLS):c.938C>T (p.Pro313Leu)Pathogenic
Global developmental delay, progressive ataxia, and elevated glutamine
β˜†β˜†β˜†β˜†2025β†’ Residue 313
NM_014905.5(GLS):c.-212GCA[680]Pathogenic
Global developmental delay, progressive ataxia, and elevated glutamine
β˜†β˜†β˜†β˜†2025
NM_014905.5(GLS):c.1940C>T (p.Thr647Ile)Likely pathogenic
Esophageal atresia/tracheoesophageal fistula
β˜†β˜†β˜†β˜†2019β†’ Residue 647
View on ClinVar β†—
Drug Targets1
TELAGLENASTATPhase II
Glutaminase kidney isoform, mitochondrial inhibitor
breast cancer
Related Genes
EPRS1Protein interaction98%GGCTProtein interaction97%EARS2Protein interaction96%GGT6Protein interaction95%ALDH1B1Protein interaction95%CPS1Protein interaction94%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
80%
Lung
56%
Heart
55%
Ovary
35%
Liver
12%
Gene Interaction Network
Click a node to explore
GLSEPRS1GGCTEARS2GGT6ALDH1B1CPS1
PROTEIN STRUCTURE
Preparing viewer…
PDB5U0I Β· 1.42 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.23LoF Tolerant
pLIβ“˜
0.06Tolerant
Observed/Expected LoF0.59 [0.31–1.23]
RankingsWhere GLS stands among ~20K protein-coding genes
  • #2,028of 20,598
    Most Researched206 Β· top 10%
  • #2,270of 5,498
    Most Pathogenic Variants18
  • #12,994of 17,882
    Most Constrained (LOEUF)1.23
Genes detectedGLS
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells.
PMID: 33991485
Mol Cell Β· 2021
1.00
2
YTHDF1 regulates GID8-mediated glutamine metabolism to promote colorectal cancer progression in m6A-dependent manner.
PMID: 39151722
Cancer Lett Β· 2024
0.90
3
The unique catalytic properties of PSAT1 mediate metabolic adaptation to glutamine blockade.
PMID: 39192144
Nat Metab Β· 2024
0.80
4
Association between
PMID: 37258469
Front Biosci (Landmark Ed) Β· 2023
0.70
5
Glutaminase inhibitors: a patent review.
PMID: 30273516
Expert Opin Ther Pat Β· 2018
0.68